US equities
|
SPCX
$166.91
▲+5.00%
NVDA
$236.84
▲+1.24%
MU
$1,064.65
▼-0.95%
TSLA
$377.06
▲+1.75%
MSFT
$525.08
▲+1.46%
SNDK
$1,707.24
▼-0.74%
INTC
$117.46
▼-1.57%
META
$742.92
▲+2.04%
SPCX
$166.91
▲+5.00%
NVDA
$236.84
▲+1.24%
MU
$1,064.65
▼-0.95%
TSLA
$377.06
▲+1.75%
MSFT
$525.08
▲+1.46%
SNDK
$1,707.24
▼-0.74%
INTC
$117.46
▼-1.57%
META
$742.92
▲+2.04%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Altimmune, Inc. - Common Stock
(NQ:
ALT
)
2.680
-0.050 (-1.83%)
Delayed Quote
Updated: 12:10 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Altimmune, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Earnings Scheduled For August 12, 2025
↗
August 12, 2025
Via
Benzinga
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Altimmune, Inc. and Encourages Investors to Contact the Firm
August 11, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
Uncovering Potential: Altimmune's Earnings Preview
↗
August 11, 2025
Via
Benzinga
Lost Money on Altimmune, Inc. (ALT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
August 11, 2025
Via
TheNewswire.com
Topics
Fraud
Lawsuit
Lost Money on Altimmune, Inc. (ALT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
August 11, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
August 09, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALT
August 08, 2025
Via
TheNewswire.com
Topics
Fraud
Lawsuit
Levi & Korsinsky Notifies Altimmune, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ALT
August 08, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
August 07, 2025
From
The Rosen Law Firm, P.A.
Via
Business Wire
Levi & Korsinsky Notifies Shareholders of Altimmune, Inc. (ALT) of a Class Action Lawsuit and an Upcoming Deadline
August 07, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
Levi & Korsinsky Notifies Shareholders of Altimmune, Inc. (ALT) of a Class Action Lawsuit and an Upcoming Deadline
August 07, 2025
Via
TheNewswire.com
Topics
Fraud
Lawsuit
Investor Alert: Robbins LLP Informs Investors of the Altimmune, Inc. Class Action Lawsuit
August 06, 2025
From
Robbins LLP
Via
GlobeNewswire
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 06, 2025
From
The Schall Law Firm
Via
Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
August 06, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
August 05, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
August 01, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
July 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
July 23, 2025
From
Pomerantz LLP
Via
GlobeNewswire
ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm
July 19, 2025
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
July 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Altimmune, Inc. - ALT
July 14, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
July 10, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
July 10, 2025
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
July 03, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
July 01, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
June 30, 2025
Via
ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
June 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Benzinga Bulls And Bears: Nvidia, Micron, HIMS — And Markets Soar On Mideast And Tariff Relief
↗
June 28, 2025
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Via
Benzinga
Altimmune's Fatty Liver Candidate Faces Differentiation Doubts
↗
June 27, 2025
Trucchio sees 48-week data as key for Phase 3 progress, while William Blair questions drug's impact on fibrosis and weight loss at 24 weeks.
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. - ALT
June 26, 2025
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
